{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T19:29:57Z","timestamp":1648927797994},"reference-count":7,"publisher":"Medwave Estudios Limitada","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medwave"],"DOI":"10.5867\/medwave.2015.02.6082","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T16:11:09Z","timestamp":1425917469000},"page":"e6082-e6082","source":"Crossref","is-referenced-by-count":0,"title":["Is iloprost effective in secondary Raynaud\u2019s phenomenon?"],"prefix":"10.5867","volume":"15","author":[{"given":"Nicole","family":"Lustig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Rada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3888","published-online":{"date-parts":[[2015,3,9]]},"reference":[{"issue":"7","key":"ref0","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.apmr.2011.01.022","article-title":"Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review.","volume":"92","author":"Huisstede","year":"2011","unstructured":"Huisstede BM, Hoogvliet P, Paulis WD, van Middelkoop M, Hausman M, Coert JH, et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil. 2011 Jul;92(7):1166-80. | CrossRef | PubMed |","journal-title":"Arch Phys Med Rehabil","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9993","issn-type":"print"},{"issue":"2","key":"ref1","first-page":"CD000953","article-title":"Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.","author":"Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2):CD000953. | CrossRef | PubMed |","journal-title":"Cochrane Database Syst Rev","ISSN":"http:\/\/id.crossref.org\/issn\/1469-493X","issn-type":"print"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.47.1.43","volume":"47","author":"Tingey","year":"1988","unstructured":"Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013 Sep;65(9):1460-71. | CrossRef | PubMed | Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis. 1995 Mar;54(3):197-200. | PubMed | Link | Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol. 1992 Sep;19(9):1403-6. | PubMed | McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis. 1988 Jan;47(1):43-7. | PubMed | Link |","journal-title":"Ann Rheum Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4967","issn-type":"print"},{"issue":"4","key":"ref3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","article-title":"Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.","volume":"41","author":"Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998 Apr;41(4):670-7. | PubMed |","journal-title":"Arthritis Rheum","ISSN":"http:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"issue":"9","key":"ref4","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.","volume":"19","author":"Wigley","year":"1992","unstructured":"Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992 Sep;19(9):1407-14. | PubMed |","journal-title":"J Rheumatol","ISSN":"http:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.","volume":"120","author":"Wigley","year":"1994","unstructured":"Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994 Feb 1;120(3):199-206. | CrossRef | PubMed |","journal-title":"Ann Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref6","unstructured":"Yardumian DA, Isenberg DA, Rustin M, Belcher G, Snaith ML, Dowd PM, et al. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol. 1988 Jun;27(3):220-6. | CrossRef | PubMed | Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis. 2008 May;67(5):703-9. | PubMed | Gladue H, Maranian P, Paulus HE, Khanna D. Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. Arthritis Care Res (Hoboken). 2013 Apr;65(4):630-6. | CrossRef | PubMed | Kowal-Bielecka O, Landew\u00e9 R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May;68(5):620-8. | CrossRef | PubMed | Aberer E. Offene, monozentrische, randomisierte, placebo-kontrollierte, einfach blinde und Observer-blinde klinische Studie bei PatientInnen mit Raynaud Syndrom mit \/ ohne progressiver systemischer Sklerodermie zur systemischen Therapie mit Iloprost versus Placebo - iloprost in raynaud. 2006. | Link | (NCRR) NCfRR. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis. 2000. [on line] | Link | ITALFARMACO. Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study. 2005. [on line] | Link | (UK) UoD. Cardiovascular events and mortality in systemic sclerosis (SSc): a study of the effect of iloprost on these and on disease progression. ISRCTN Registry 2002. [on line] | Link |"}],"container-title":["Medwave"],"original-title":["\u00bfEs efectivo el iloprost en el fen\u00f3meno de Raynaud secundario?"],"link":[{"URL":"https:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:55:55Z","timestamp":1562846155000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6082.act"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,9]]},"references-count":7,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2015,3,9]]}},"URL":"https:\/\/doi.org\/10.5867\/medwave.2015.02.6082","relation":{},"ISSN":["0717-6384"],"issn-type":[{"value":"0717-6384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,9]]}}}